Contrasting China Health Industries (OTCMKTS:CHHE) & Tarsus Pharmaceuticals (NASDAQ:TARS)

China Health Industries (OTCMKTS:CHHE) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership and profitability.

Analyst Ratings

This is a summary of recent ratings for China Health Industries and Tarsus Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China Health Industries	0	0	0	0	0.00
Tarsus Pharmaceuticals	1	2	4	2	2.78

Tarsus Pharmaceuticals has a consensus target price of $90.67, indicating a potential upside of 46.35%. Given Tarsus Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Tarsus Pharmaceuticals is more favorable than China Health Industries.

Institutional & Insider Ownership

90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. 31.3% of China Health Industries shares are owned by insiders. Comparatively, 9.6% of Tarsus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares China Health Industries and Tarsus Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
China Health Industries	N/A	N/A	N/A
Tarsus Pharmaceuticals	-9.02%	-14.19%	-8.89%

Earnings & Valuation

This table compares China Health Industries and Tarsus Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China Health Industries	$110,000.00	0.00	-$410,000.00	($0.02)	N/A
Tarsus Pharmaceuticals	$451.36 million	5.90	-$66.42 million	($1.14)	-54.34

China Health Industries has higher earnings, but lower revenue than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than China Health Industries, indicating that it is currently the more affordable of the two stocks.

About China Health Industries

China Health Industries Holdings, Inc., through its subsidiaries, manufactures and sells health products. The company operates through three segments: Humankind, HLJ Huimeijia, and Others. The company offers hemp derivative products, such as hemp oil, hemp protein powder, hemp polypeptides, collagen peptides, hemp essence repair lotions, hemp revitalizing essence products, hemp anti-aging brightening eye creams, hemp frozen age nourishing creams, hemp seed beers, and hemp seeds. It also provides health supplements, including Sailuozhi soft capsule, which is made from frog oil, soybean isoflavone, procyanidine, and vitamin E for freckle removal and skin moisture supplements under the QunLe brand; and propolis and black ant capsule that is made from propolis, black ant, acanthopanax, and astragalus root under the Kindlink brand. In addition, the company offers health products for acne removal, relieving eyestrain, enhancing bone density, enhancing memory, enhancing nutritional anemia and chloasma, relaxing bowels and promoting the discharge of lead, enhancing immunity and relieving physical fatigue, and dispelling chloasma, as well as iron and multivitamin, and mineral supplements. Further, it manufactures and sells various types of medical drugs, such as enema glycerini, umguentumacidi borici camphoratum, ge hong beriberi water, pelvic inflammation suppository, injury and paralysis tincture, indometacin and furazolidone suppositories, injury and rheumatism relieving paste, refining goupi cream, muskiness pain relieving paste, muskiness bone strengthener paste, matrine suppositories, ethacriding lactate solution, iodine tincture, mercurochrome solution, hydrogen peroxide solution, halcinonide cream, compound fluocinonide tincture, and policresulen vaginal suppository. The company primarily sells its products through sales personnel and sales agents. China Health Industries Holdings, Inc. was founded in 1996 and is based in Harbin City, the People's Republic of China.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.